The strong Phase 1 data and accelerated development of PLN-101095 represent a significant value inflection point. The extended cash runway reduces near-term dilution risk. Traders should monitor upcoming interim data from the Phase 1b trial in 2027 as a key catalyst.
PLRX drugs
PLRX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $1.41entry
- T+1 · 8mo ago −4.26%α −3.66% · $1.35
- T+5 · 8mo ago −5.67%α −4.70% · $1.33
- T+20 · 7mo ago −9.22%α −11.19% · $1.28
- T+60 · 5mo ago −18.44%α −29.14% · $1.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pliant Therapeutics reported fourth quarter 2025 financial results and provided a corporate update, highlighting positive Phase 1 data for its oncology drug PLN-101095 in checkpoint inhibitor-refractory solid tumors. The company initiated a Phase 1b indication expansion trial and reported reduced R&D and G&A expenses, leading to a narrower net loss. It has $192.4 million in cash, sufficient to fund operations into the second half of 2028.
Key Financial Metrics
Key Facts
- PLN-101095 showed deep and durable responses in ICI-refractory patients, with 4 responders (1 complete, 3 partial) out of 10 patients across multiple tumor types.
- Phase 1b indication expansion trial initiated in NSCLC, renal cell carcinoma, and high tumor mutational burden tumors, with first patient enrollment expected in Q2 2026 and interim data in 2027.
- Q4 2025 R&D expenses decreased to $15.6M from $38.8M YoY due to discontinuation of BEACON-IPF.
- Q4 2025 G&A expenses decreased to $8.0M from $14.5M YoY due to workforce restructuring.
- Net loss narrowed to $23.6M from $49.7M YoY.
- Cash, cash equivalents, and short-term investments totaled $192.4M as of December 31, 2025, expected to fund operations into H2 2028.
Financial Impact
R&D expenses down 60% YoY, G&A down 45% YoY, net loss down 52.5% YoY, with cash runway extending into 2028.
Risk Factors
- Clinical development risk: PLN-101095 is still in early stages; future trial results may not replicate initial success.
- Dilution risk: Despite current cash runway, future financing may be required for later-stage trials, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001746473-26-000039 |
| Document: plrx-20260311.htm | 0001746473-26-000039 |
| Document: 0001746473-26-000039-index-headers.html | 0001746473-26-000039 |
| Document: 0001746473-26-000039-index.html | 0001746473-26-000039 |
| Document: 0001746473-26-000039.txt | 0001746473-26-000039 |
Track record
8 reports on PLRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Viewing Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers